Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Wuyts (Leuven, Belgium), C. Dahlqvist (Yvoir, Belgium), H. Slabbynck (Antwerp, Belgium), M. Schlesser (Luxembourg City, Luxembourg), N. Gusbin (Liège, Belgium), C. Compere (Brussels, Belgium), S. Maddens (Kortrijk, Belgium), K. Kirchgaessler (Basel, Switzerland), K. Bartley (South San Francisco, CA, United States of America), B. Bondue (Brussels, Belgium). Functional decline over time in patients with IPF treated with pirfenidone: the PROOF registry. 2201

Member's Comments

No comment yet.

Related content which might interest you: The effect of treatment with pirfenidone on death or lung transplantation in patients with idiopathic pulmonary fibrosis (IPF): Analysis of outcomes in the CAPACITY (CAP) trials Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Efficacy of tiotropium/olodaterol on sedentary/active time in COPD patients: VESUTO study Source: International Congress 2018 – COPD management Year: 2018 The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Health and functional status of tiotropium/olodaterol-treated patients with COPD: results from the AERIAL® non-interventional study Source: ERJ Open Res, 7 (3) 00004-2021; 10.1183/23120541.00004-2021 Year: 2021 Effect of pirfenidone on treatment-emergent (TE) all-cause mortality (ACM) in patients with idiopathic pulmonary fibrosis (IPF): Pooled data analysis from ASCEND and CAPACITY Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Patterns of discontinuation in patients with IPF treated with open-label nintedanib: data from INPULSIS-ON Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Evaluation of roflumilast in COPD patients in a real-world European setting: results from the PROFILE EU study Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017 Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Predictors of lung function decline: a retrospective study in COPD patients Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018 2-Year survival of patients with IPF with or without GERD: a study using VA national database Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Annual rate of FVC decline in patients with IPF treated with pirfenidone: Pooled analysis from 3 pivotal studies Source: International Congress 2016 – IPF treatment I Year: 2016 Health status changes in COPD patients after real-life switch from tiotropium or salmeterol/fluticasone to indacaterol/glycopyrronium using the EQ-5D-3L instrument: results from the POWER study Source: International Congress 2018 – COPD management Year: 2018 Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Disease progression at 12 months does not predict future outcomes in IPF patients: Analysis from the Australian IPF Registry Source: International Congress 2017 – ILDs: clinical aspects Year: 2017